banner pipeline


CyTuVax’ goal is to develop effective vaccines for which a high medical need exist. The CyTuVax vaccines can generate powerful immune responses and are primarily designed for cancer immunotherapy.

CyTuVax’ major aim is developing a pipeline in oncology based on the wide applicability of our tumor vaccination & adjuvant technology. As a first human target, CyTuVax will focus on the development of the pancreas cancer vaccine PanCaVax. Another target is the development of a vaccine against melanoma, for which promising preclinical studies have been completed.

In the clinical development of the pancreas cancer vaccine CyTuVax is cooperating with the Pancreas Cancer Center of the University Hospital Bochum and Prof. Eric van Cutsem of the University Hospital Leuven.

For the development of a tumor vaccine for melanoma, CyTuVax will cooperate with Dr. Christian Blank (Anthony van Leeuwenhoek Hospital in Amsterdam) and with Dr. Rob Janssen of the Maastricht UMC.

The second activity is in the field of viral and bacterial vaccines. CyTuVax has received authorization from the Dutch authority CCMO to start its Phase I clinical study of HBAI20, a specialty vaccine for Hepatitis B non-responders in October 2015 ( NCT02540538). Testing the AI20 adjuvant in the Hepatitis B Phase I study will provide data on its safety and efficacy, which will strengthen the value of our technology platform.

Another vaccine being currently developed is the cytomegalovirus (CMV) vaccine for transplant recipients.


Latest news

showCyTuVax is currently testing its vaccine technology in a clinical Phase 2 study of a vaccine for hepatitis B non-responders

Where we are

About us

CyTuVax B.V.
Oxfordlaan 55
6229 EV Maastricht
The Netherlands

This email address is being protected from spambots. You need JavaScript enabled to view it.